uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B ~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infusions or Reported...